Lung transplantation is the only successful treatment option for endstage lung diseases. Over the last decades, lung transplantation has steadily improved, and in parallel, indications were broadened and contraindication eased. While the demand is still increasing worldwide, a chronic organ shortage remains the primary limiting factor in lung transplantation. A concerning wait-list mortality is currently reported by the Organ Procurement and Transplantation Network (OPTN), increasing within a decade from 15% to 20%. 1 Since more than 50 years, donation after brain death (DBD) has been the leading source of deceased donation worldwide. In DBD donors, the lung is the most fragile and vulnerable of all solid organs, and only 15%-30% of these lungs are generally utilized for transplantation. 1 One reason is a neurogenic pulmonary edema caused by upregulation of inflammatory mediators attributed to brain death. Besides this, lungs are vulnerable due to frequent aspiration of gastric contents, pulmonary infections, contusion, and ventilation-associated lung injury. To overcome the critical organ shortage, many centers have started to use marginal donor lungs, size reduced allografts, and, in few cases, living lobar donation. However, the latter attempts have just led to a small increase in the donor pool so far. In contrast, the